名称 | GW9662 |
描述 | GW9662 (TIMTEC-BB SBB006523) is a specific PPARγ antagonist (IC50: 3.3 nM, in a cell-free assay), with 100 to 1000-fold functional selectivity for PPARγ than PPARα/δ in cells. |
细胞实验 | MDA-MB-231 cells are seeded at a density of 1 × 105 cells per 25 cm3 tissue culture flask. After 24 h (day 0), the growth medium is replaced with fresh medium containing rosiglitazone (50 μM), GW9662 (10 μM) or both together. Control flasks receives 0.1% DMSO. Cells are harvested on days 0, 3, 5, 7, 10 for each treatment condition by trypsinisation, stained using trypan blue, and the total and viable number of cells per flask calculates using a haemocytometer.(Only for Reference) |
激酶实验 | Binding assay: The human PPARα, PPARγ, and PPARδ ligand binding domains (LBDs) are expressed in E. coli as polyhistidine-tagged fusion proteins. Receptors are immobilized on SPA beads by addition of the desired receptor (15 nM) to a slurry of streptavidin-modifed SPA beads (0.5 mg/mL) in assay buffer. The mixture is allowed to equilibrate for at least 1 hour at room temperature, and the beads are pelleted by centrifugation at 1×103 g. The supernate is discarded, and the beads are resuspended in the original volume of fresh assay buffer with gentle mixing. The centrifugation/resuspension procedure is repeated, and the resulting slurry of receptor-coated beads is used immediately or stored at 4 ℃ for up to 1 week before use. [3H]GW2443 are used as radioligands for determination of competition binding to PPARα, PPARγ, and PPARδ, respectively. Unless otherwise indicated, the buffer used for all assays is 50 mM HEPES (pH 7), 50 mM NaCl, 5 mM CHAPS, 0.1 mg/mL BSA, and 10 mM DTT. For some experiments, the HEPES (pH 7) is replaced with 50 mM Tris (pH 8). |
体外活性 | GW9662 inhibits the activation of PPARγ and suppresses the growth of human breast cancer cell lines (MCF7, MDA-MB-468, MDA-MB-231) with IC50 values of 20-30 μM. It binds to Cys(285) on PPARγ, a site conserved across the three types of PPAR. When used alongside Rosiglitazone (50 μM) for seven days in MDA-MB-231 cells, a statistically significant reduction in cell viability is observed. In primary mouse bone marrow and RAW264.7 cells, GW9662 (2 μM) can concentration-dependently reverse the inhibitory effects of PPARγ1 ligands on RANKL-induced osteoclastogenesis. Additionally, GW9662 (1 μM) inhibits RANKL-activated NF-κB in RAW264.7 cells, and at a concentration of 2 μM, it blocks the suppressive effect of IL-4 on osteoclastogenesis in BM cells. In primary preadipocytes from patients with thyroid eye disease, GW9662 (10 μM) inhibits hormone and agonist-induced adipocyte differentiation. |
体内活性 | Pretreatment with lipopolysaccharide (1 mg/kg, i.p.) significantly mitigates all characteristics of ischemia/reperfusion injury manifesting as renal damage and dysfunction in rats. However, this protective effect of lipopolysaccharide can be inhibited by GW9662 (1 mg/kg, i.p.). |
存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 45 mg/mL (162.64 mM), Sonication is recommended. Ethanol : 6.9 mg/mL (25 mM)), Heating is recommended.
|
关键字 | GW9662 | Peroxisome proliferator-activated receptors | PPAR | TIMTEC-BB SBB 006523 | TIMTEC-BB SBB-006523 | Inhibitor | inhibit | GW-9662 |
相关产品 | PHYTOL | Daidzein | Gemfibrozil | Fenofibrate | Pioglitazone hydrochloride | 5-Aminosalicylic Acid | Naringenin | Fisetin | 2,3-Butanediol | Icariin |
相关库 | 核受体化合物库 | 糖代谢化合物库 | 抗胰腺癌化合物库 | 神经退行性疾病化合物库 | 经典已知活性库 | 抗阿尔茨海默症化合物库 | 抑制剂库 | 抗衰老化合物库 | 已知活性化合物库 | 抗代谢疾病化合物库 |